Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 20/20 | 1.00 |
| ▸ | MAOA | P21397 | 19/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067289 | 1.00 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL7215662 | 0.97 | MAOB (0.94) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL2524800 | 0.91 | MAOB (0.84) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL30353268 | 0.91 | MAOB (0.84) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL7218099 | 0.91 | MAOB (0.82) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL226640 | 0.89 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL6309072 | 0.86 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL7184607 | 0.86 | MAOA (0.76) | MAOBMAOANPC1RAB9A | |
| SCHEMBL15414670 | 0.86 | MAOB (0.81) | MAOBMAOA | |
| SCHEMBL3451690 | 0.86 | MAOB (0.94) | MAOBMAOANPC1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074043-A | Combination therapy with KRAS modulators | 光达治疗公司 | 2026-05-22 | — | — | CN | disclosed |
| CN-122059824-A | Synthesis method of ilalastyl chiral intermediate | 上海格苓凯生物科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12624052-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119110804-A | KRAS modulators and uses thereof | 光达治疗公司 | 2024-12-10 | — | — | CN | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-6057329-A | Fused polycyclic 2-aminopyrimidine derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-05-02 | — | — | US | disclosed |
| EP-0946523-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028281-A1 | FUSED POLYCYCLIC 2-AMINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PROTEIN TYROSINE KINASE INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-07-02 | — | — | WO | disclosed |
| EP-0606661-B1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | HOFFMANN LA ROCHE (CH) | 1997-03-12 | — | — | EP | disclosed |
| US-5597826-A | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5504104-A | TREATING INFECTIONS OR DISEASES CAUSED BY RETROVIRUSES, SUCH AS HIV AND AIDS | WARNER-LAMBERT COMPANY (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0701819-A2 | Novel compositions containing sertraline and a 5-HT1D receptor agonist or antagonist | PFIZER INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| US-5385947-A | For prevention of nerve damage due to reduction of blood or oxygen supplies | HOFFMANN-LA ROCHE INC. (US) | 1995-01-31 | — | — | US | disclosed |
| WO-1994021619-A1 | NAPHTHALENE DERIVATIVES | PFIZER INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| EP-0606661-A1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1994-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042921-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MAOB 4870/4885MAOA 4881/4885NPC1 3122/4885 |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | MAOB 4875/4885MAOA 4885/4885NPC1 3193/4885 |
| US-12624052-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MAOB 4747/4885MAOA 4851/4885NPC1 1014/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | MAOB 4875/4885MAOA 4885/4885NPC1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.